CARsgen Therapeutics Holdings Limited (HK:2171), a Chinese developer of innovative CAR T-cell therapies, said on Sunday that it has presented clinical data from a study of its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) at the 67th American Society of Hematology (ASH) Annual Meeting.

The poster was titled 'A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma'.

Eight patients with R/R MM were enrolled in the dose-escalation phase and received CT0596 infusion. The median number of prior lines of therapy was 4.5 (range: 3-9).

As of 31 August 2025, all eight infused patients were evaluable for efficacy, with a median follow-up of 4.14 months. Six patients achieved a partial response (PR) or better: three achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), one achieved very good partial response (VGPR), and two achieved PR. Among the six patients who received full-dose lymphodepletion, five achieved PR or better. Six patients in the full-dose lymphodepletion group achieved minimal residual disease (MRD)-negativity at Week 4. CAR-T cell expansion was observed in all eight patients.

The study is still in its dose-exploration phase.